Home / Psoriasis (page 5)


Here you will find the latest clinical research on psoriasis.

Guselkumab front and center at EADV Congress

edav dermatology conference

Due to the combination of efficacy, safety, and convenience, the interleukin (IL)-23 inhibitors will represent a “significant broadening” of the therapeutic armamentarium for moderate-to-severe psoriasis, according to Prof. Dr. Kristian Reich of Dermatologikum Hamburg in Hamburg, Germany. Dr. Reich spoke on how IL-23 inhibitors fit into the psoriasis treatment armamentarium in …

Read More »

Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA (MUST)

  Purpose Methotrexate (MTX) co-medication can improve the therapeutic effect of biological therapies (e.g. Tumor necrosis factor (TNF) -inhibitors) in rheumatoid arthritis (RA), but its role in Psoriatic Arthritis (PsA) remains unclear. No data from Randomized Clinical Trials (RCTs) are available to address the questions whether add-on of MTX to …

Read More »

Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis

  Purpose An international, multi-centre, prospective, non-controlled, open, single-group, 8-week trial in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis. Condition Intervention Phase Psoriasis Vulgaris Drug: LEO 80185 Phase 2 Study Type: Interventional Study Design: Intervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: …

Read More »

The Role of Bacterial Toxins in Human Skin Disease

  Purpose Atopic dermatitis and psoriasis are two skin diseases often associated with bacterial infections and inflammation. Studies indicate that skin cells from these patients may have some changes that make these patients more susceptible to bacterial infections. Inflammatory environment may have an effect on the function of skin cells. …

Read More »

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

  Purpose This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis. Condition Intervention Phase Plaque Psoriasis Drug: PF-06826647 tablet Drug: PF-06826647 oral suspension Other: Placebo oral solution/suspension Other: Placebo tablet Phase 1 Study Type: …

Read More »

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

  Purpose The purpose of this study is to investigate the effect of BMS-986165 in combination with an oral contraceptive in healthy female patients. Condition Intervention Phase Systemic Lupus Erythematosus Arthritic Psoriasis Psoriasis Inflammatory Bowel Diseases Drug: BMS-986165 Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol) Phase 1 …

Read More »